Core Viewpoint - The research reveals a new mechanism of immune evasion in KRAS-mutant colorectal cancer (CRC), highlighting the potential of targeting the TRIP6–ENO2–CD44 lactylation signaling axis as a promising strategy to overcome resistance to immunotherapy [3][8]. Group 1: Research Findings - The study identifies TRIP6 phosphorylation as a key mechanism for immune evasion in KRAS-mutant CRC [6]. - In KRAS wild-type CRC cells, unphosphorylated TRIP6 binds to KDM1A, inhibiting ENO2 expression and limiting glycolysis [6]. - In KRAS-mutant CRC cells, ERK1/ERK2-mediated TRIP6 phosphorylation disrupts this interaction, enhancing glycolysis and lactate production, which leads to increased lactylation of CD44 on CD8+ T cells [6]. Group 2: Implications for Treatment - Elevated extracellular lactate levels impair CD8+ T cell function by damaging hyaluronic acid binding and AKT signaling [6]. - The research team developed a specific blocking peptide, mPT6, which restores T cell function and enhances the efficacy of PD-1 immunotherapy in preclinical models [6][8]. - The findings suggest that targeting the TRIP6–ENO2–CD44 lactylation axis could be a viable approach to address immunotherapy resistance in KRAS-mutant CRC [8].

Core Findings - The research reveals that the steroid metabolite pregnenolone (P5) promotes tumor immune evasion by inhibiting endogenous retrovirus (ERV) expression, providing a potential new target for enhancing the efficacy of solid tumor immunotherapy [2][3][6]. Mechanism of Action - Pregnenolone (P5) directly binds to Kap1, inhibiting Trim39-mediated ubiquitination at the K750 site, preventing its degradation and leading to abnormal accumulation of Kap1 in cells, which in turn suppresses ERV expression that activates type I interferon (IFN-I) production in tumor cells [3][4]. - The study demonstrates that competitive inhibitor P5-ol can counteract the stabilizing effect of pregnenolone on Kap1, reactivating ERV expression and inducing a natural immune response, effectively inhibiting tumor growth and enhancing the efficacy of immunotherapy (PD-1 antibody) [4]. Implications for Cancer Treatment - The findings establish a previously unrecognized link between mating-related steroid metabolism and tumor immune regulation, suggesting that pregnenolone signaling may serve as a potential new target for cancer treatment [6]. - The study indicates that abstinence activates the hypothalamic-pituitary-adrenal (HPA) signaling axis, leading to increased production of pregnenolone, which promotes tumor progression [7]. - Pregnenolone antagonists are identified as promising candidates for anti-tumor therapy [7].

Core Viewpoint - AstraZeneca's drug Imfinzi (durvalumab) has been approved by China's National Medical Products Administration (NMPA) for first-line treatment of adult patients with mismatch repair deficient (dMMR) advanced or recurrent endometrial cancer, in combination with carboplatin and paclitaxel, followed by monotherapy maintenance [1]. Group 1: Drug Approval and Mechanism - Imfinzi is a humanized PD-L1 monoclonal antibody that binds to the PD-L1 protein, blocking its interaction with PD-1 and CD80, thereby preventing tumor immune evasion and restoring suppressed immune responses [1]. - The approval in China is based on subgroup analysis results from the DUO-E Phase III trial, which is a three-arm, randomized, double-blind, placebo-controlled, multicenter study [1]. Group 2: Clinical Trial Results - In the trial, the combination of durvalumab with carboplatin and paclitaxel, followed by durvalumab monotherapy maintenance, reduced the risk of disease progression or death by 58% compared to the control group [2]. - The median progression-free survival (PFS) for the durvalumab group has not yet been reached, while the median PFS for the control group is 7.0 months [2]. Group 3: Safety Profile - The overall safety and tolerability of the durvalumab combination therapy are good, consistent with previous clinical trial results, and no new safety signals have been reported [2].

Core Viewpoint - The study identifies TRAP1 as a mitochondrial chaperone that is suppressed by cancer, leading to immune evasion, and suggests that restoring TRAP1 can reprogram tumor-associated macrophages (TAM) to enhance anti-tumor immunity, positioning the TRAP1 pathway as a promising new target for cancer immunotherapy [2][9]. Group 1 - TRAP1 is a mitochondrial HSP90 molecular chaperone that acts as a metabolic checkpoint, inhibiting oxidative respiration and limiting the suppressive function of macrophages [5]. - In the tumor microenvironment, TRAP1 expression is downregulated through the TIM4-AMPK signaling pathway, and its absence enhances immune suppressive activity while promoting tumor immune evasion [6]. - Inhibition of TRAP1 increases electron transport chain activity and raises the ratio of α-ketoglutarate to succinate, reshaping mitochondrial homeostasis and leading to enhanced immune suppression through JMJD3-mediated histone demethylation [6]. Group 2 - Targeting TIM4 and JMJD3 to restore TRAP1 can reprogram TAM, disrupt the immune evasion of the tumor microenvironment, and enhance anti-tumor immunity [7]. - The findings establish TRAP1 as a key regulatory factor integrating metabolic and epigenetic control of suppressive TAM functions, highlighting the TRAP1 pathway as a promising new target for cancer immunotherapy [9].

Core Viewpoint - The study reveals that targeting dihydroorotate dehydrogenase (DHODH) to inhibit macropinocytosis in tumor cells is a potential method to reverse immunosuppression and improve cancer immunotherapy [8]. Group 1: Key Findings - High-throughput screening identified DHODH as essential for cancer cell macropinocytosis [6]. - DHODH maintains the O-GlcNAc glycosylation modification and membrane localization of neuropilin-1 (NRP1), promoting macropinocytosis [6]. - Macropinocytosis increases the acetylation of transcription factor CIITA, leading to the suppression of major histocompatibility complex class II (MHC II) expression, thereby facilitating immune evasion [6]. Group 2: Implications for Immunotherapy - Inhibition of DHODH in cancer cells significantly enhances immune cell infiltration and activates anti-tumor immune responses, overcoming resistance to anti-PD-1 therapy [5][6]. - High expression levels of DHODH and NRP1 in human breast and lung cancer tissues correlate with poor patient prognosis [5].

Core Viewpoint - Recent studies reveal that taurine, a common ingredient in energy drinks, plays a significant role in leukemia progression by driving glycolysis in the tumor microenvironment, suggesting caution in its supplementation for leukemia patients [2][9]. Group 1: Taurine's Role in Leukemia - A study from the University of Rochester indicates that taurine from the tumor niche promotes glycolysis, facilitating leukemia development [2]. - The research utilized single-cell RNA sequencing to identify molecular interactions between the bone marrow microenvironment and leukemia stem cells (LSC), highlighting the importance of these interactions in leukemia progression [5]. - Taurine biosynthesis driven by cysteine dioxygenase-1 (CDO1) is limited to osteoblast lineage cells and increases during myeloid disease progression, with LSC relying on taurine transport proteins for their growth [5][6]. Group 2: Implications for Treatment - Inhibition of taurine transport proteins significantly suppresses the progression of acute myeloid leukemia (AML) in mouse models and human patient-derived cells [6]. - Elevated expression of taurine transport proteins in venetoclax-resistant AML patients suggests a potential therapeutic target, as inhibiting these proteins can enhance the efficacy of existing treatments [6]. - The study indicates that taurine uptake deficiency reduces leukemia stem cell capabilities by inhibiting mTOR activation and downstream glycolysis [6]. Group 3: Broader Research Context - Other studies have linked taurine deficiency to aging and its potential to extend healthspan in various organisms, indicating its multifaceted role in health and disease [9][11]. - Research has shown that taurine supplementation can reactivate exhausted CD8+ T cells, enhancing cancer treatment outcomes, further complicating the narrative around taurine's role in cancer [11]. - The discovery of a novel N-acetyltaurine hydrolase (PTER) suggests new avenues for obesity treatment, indicating taurine's relevance beyond oncology [14].